To delve deeper into the therapeutic potential of HDAC inhibitors, researchers conducted preclinical experiments using suberoylanilide hydroxamic acid (SAHA), a powerful HDAC inhibitor, in the context of the R6/2 HD mouse model. This evidence concerns the gene HDAC9 and Huntington disease.